OSpaad

OSpaad performs consensus survival analysis for pancreatic adenocarcinoma by integrating gene expression and long-term clinical follow-up to identify and validate prognostic biomarkers.

Key Features:

• Comprehensive Dataset: Integrates gene expression profiling with long-term follow-up from 1319 unique pancreatic adenocarcinoma cases across seven cohorts.
• Survival Analysis Terms: Provides four survival endpoints: overall survival, disease-specific survival, disease-free interval, and progression-free interval.
• Subgroup Analysis: Performs subgroup analyses using clinical confounders including TNM stage, sex, smoking history, lymph node invasion, and race.
• Validation of Prognostic Biomarkers: Validated 97% (116 of 120) previously reported prognostic biomarkers, including ERBB2, TP53, and EGFR.

Scientific Applications:

• Prognostic biomarker assessment: Evaluate the prognostic significance of individual genes in pancreatic adenocarcinoma using multiple survival endpoints.
• Biomarker validation: Confirm previously reported prognostic biomarkers, as demonstrated by validation of 116 of 120 candidates.
• Subgroup-specific prognosis: Assess survival differences within clinical subgroups defined by TNM stage, sex, smoking history, lymph node invasion, and race.

Methodology:

Integrates gene expression data with clinical follow-up from 1319 pancreatic adenocarcinoma cases across seven cohorts to perform survival analysis using the four specified endpoints and subgroup stratification by clinical variables.